Clinical Trial Update: Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib in combination with G-CHOP for untreated intermediate-high risk follicular lymphoma; study status is NOT_YET_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Gazyva (Obinutuzumab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: FL | Phase 2 | Status: NOT_YET_RECRUITING